New gene editing treatment cuts dangerous cholesterol in small study
Pro Research Analysisby 
Searched over 200M research papers
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
CRISPR/Cas9 Gene Editing for Familial Hypercholesterolemia
Recent advancements in gene editing have shown promising results in treating familial hypercholesterolemia (FH), a genetic disorder characterized by high cholesterol levels. One study utilized the CRISPR/Cas9 system delivered via adeno-associated virus (AAV) to correct mutations in the low-density lipoprotein receptor (LDLR) gene in a mouse model. This treatment led to significant reductions in total cholesterol, triglycerides, and LDL cholesterol, along with a decrease in atherosclerotic plaques and macrophage infiltration in the aorta .
PCSK9 Gene Editing in Non-Human Primates
Another significant development involves the use of CRISPR base editors to target the PCSK9 gene, which plays a crucial role in cholesterol regulation. In a study involving cynomolgus monkeys, a single infusion of lipid nanoparticles carrying CRISPR base editors resulted in a near-complete knockdown of PCSK9 in the liver. This led to a 90% reduction in blood PCSK9 levels and a 60% decrease in LDL cholesterol, with effects lasting for at least eight months .
VERVE-101: A Single-Course CRISPR Base-Editing Therapy
VERVE-101, an investigational CRISPR base-editing therapy, has shown efficacy in non-human primates. This therapy targets the PCSK9 gene to permanently reduce its expression in the liver. In treated monkeys, VERVE-101 led to a 67-83% reduction in blood PCSK9 levels and a 49-69% decrease in LDL cholesterol. The effects were durable, lasting up to 476 days post-treatment, and the therapy was well-tolerated with no significant adverse effects Lee2022Lee2022.
ANGPTL3 Gene Editing for Cholesterol Reduction
In addition to PCSK9, the ANGPTL3 gene has also been targeted for cholesterol reduction. Preclinical studies have demonstrated that CRISPR base editing can effectively inactivate ANGPTL3, leading to significant reductions in LDL cholesterol and triglycerides. This approach has shown robust and durable effects in non-human primate models, with reductions in circulating ANGPTL3 levels by up to 96% Khera2022Chadwick2018.
Safety and Efficacy of Gene Editing Therapies
The safety and efficacy of these gene editing therapies have been rigorously tested in various animal models. Studies have shown that these treatments can achieve precise and durable gene modifications with minimal off-target effects. For instance, in a study involving a humanized mouse model, CRISPR-Cas9 and base editing techniques were used to target the human PCSK9 gene, resulting in significant cholesterol reductions without off-target mutations or chromosomal translocations .
Conclusion
The recent advancements in gene editing technologies, particularly CRISPR/Cas9 and base editing, offer promising new treatments for reducing dangerous cholesterol levels in patients with familial hypercholesterolemia and other dyslipidemias. These therapies have demonstrated significant efficacy and safety in preclinical studies, paving the way for potential clinical applications and a new era in the treatment of cardiovascular diseases.
Sources and full results
Most relevant research papers on this topic
In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia
AAV-CRISPR/Cas9-mediated gene editing can partially restore LDLR expression and effectively ameliorate atherosclerosis phenotypes in Ldlr mutant mice, offering a potential therapeutic approach for familial hypercholesterolemia patients.
DOI